A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP (R-Pola-Glo)

Schmitt, Clemens (PI)
Krivic, Denis (Researcher)
Lichtenauer, Nina (Researcher)
Kühr, Thomas (Researcher)
Schneeweiß, Bruno (Researcher)
Piringer, Gudrun (Researcher)
Popp, Henning Detlef (Researcher)
Krenosz, K. J. (Researcher)
Ghanem, Riad (Researcher)
Stefan, Alex (Researcher)
Schwarz, Heike Kathleen (Researcher)
Kovacsova, Judita (Researcher)
Kausche, Lea Elisabeth (Researcher)
Stegemann, Maike (Researcher)
Klein, Katharina (Researcher)
Trathnigg, Nicolas (Researcher)

Department of Internal Medicine 3 - Hematology and Internal Oncology

Department of Internal Medicine 3 - Hematology and Internal Oncology

Project: Clinical studies › Clinical Study (Industry project)

Description

A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP

Short title	R-Pola-Glo
Status	Active
Effective start/end date	07.08.2023 → 03.01.2028

Collaborative partners

Johannes Kepler University Linz (lead)
Institut für Klinische Krebsforschung IKF GmbH (Project partner)
Arbeitsgemeinschaft Medikamentöse Tumortherapie gGmbH (Project partner)

Fields of science

302024 Haematology
302055 Oncology

Project Details

Description

Collaborative partners

Fields of science